FOR IMMEDIATE RELEASE
MEDIROM Announces Receipt of Nasdaq Delisting Notice, Filing of Annual Report and Submission of Hearing Request
TOKYO, Japan, November 18, 2026 — MEDIROM Healthcare Technologies Inc. (Nasdaq: MRM) (the “Company”) today announced that on November 13, 2026, it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) because the Company had not filed its Annual Report on Form 20-F for the year ended December 31, 2025 (the “Annual Report”) within the extension period previously granted by Nasdaq and therefore had not regained compliance with Nasdaq Listing Rule 5250(c)(1).
As previously disclosed, Nasdaq notified the Company on May 26, 2026, that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) because it had not timely filed the Annual Report. Nasdaq subsequently granted the Company an extension to regain compliance. The Company did not file the Annual Report within that extension period. The Notice stated that unless the Company requests an appeal of the delisting determination, trading of the Company’s American Depositary Shares will be subject to suspension and delisting from Nasdaq at the opening of business on November 24, 2026.
On November 18, 2026, the Company timely submitted a request for a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal the determination. Under the applicable Nasdaq rules, the hearing request automatically stays any suspension of trading in the Company’s American Depositary Shares (“ADSs”) for 15 days from the date of the request. The Notice also stated that when the Company requests a hearing, it may also request a stay of the suspension pending the hearing. The Company has requested an extended stay of any trading suspension pending completion of the hearing process.
The Company filed the Annual Report with the U.S. Securities and Exchange Commission on November 18, 2026. The Company has presented the filing of the Annual Report to Nasdaq in support of its appeal and request for continued listing. There can be no assurance that Nasdaq will determine that the filing resolves the Company’s periodic reporting deficiency or results in the cancelation of a hearing, that the Panel will grant any further stay of suspension or the Company’s request for continued listing, or that the Company will regain or maintain compliance with all applicable Nasdaq continued listing requirements.
The Notice relates to the Company’s periodic reporting deficiency. Separately, as previously disclosed, on October 6, 2026, the Company received a notice that it was not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq provided the Company until April 5, 2027, to regain compliance with that requirement. Filing the Annual Report does not resolve this separate minimum bid price deficiency.
